Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue
_blank

Advertising Opportunities

Click Here

Email A Friend Back to Archived News


Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage


Thursday, March 11, 2010

Thousand Oaks, CA -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA. The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort.

The platform technology will be subject to the FDA review and approval process, including clinical trials. It is not currently approved for use in humans.

The patent broadly protects the formation or repair of cartilage when applying a NELL-1 sequence of UCB-1 in a region where cartilage formation or repair is desired to include the method of application comprising a variety of delivery agents in surgical applications.

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. credited the company's partner, the Musculoskeletal Transplant Foundation (MTF) for its ongoing financial and strategic support. "MTF is essential to our progress toward realizing the full potential of the UCB-1 protein as a platform technology."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space. The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years. The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.



Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free